{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '11.', 'ASSESSMENTS', 'Procedures that are performed as part of standard of care should not be repeated if they are', 'within the Screening window and are done prior to signing the ICF.', '11.1.', 'Informed Consent', 'Assessments may not be performed until the patient provides written informed consent (see', 'Section 14.6).', 'SVdX/SdX patients will be required to sign a separate ICF for treatment with SVd/Sd.', '11.2.', 'Demographic and Baseline Characteristics Assessments', '11.2.1.', 'Demographics', 'Patient demographics (including date of birth, sex, race, ethnicity, and age at the time of consent)', 'will be collected.', '11.2.2.', 'Medical History', 'A complete medical history will be obtained from each patient. Medical history will include', \"baseline symptoms as well as a detailed history of prior procedures for the patient's MM and\", 'other prior cancer therapies (ie, chemotherapy, hormonal therapy, immunotherapy, biotherapy,', 'radiotherapy, and surgery), including start and end dates, best response, PD during or after', 'therapy, as well as discontinuations due to intolerability or toxicity. Smoking history will be', 'recorded. A detailed history of disease-specific diagnostic and prognostic testing and test results', '(such as phenotypic and cytogenetic profiles) will also be collected. Evaluate the risk of TLS', 'based on a clinical evaluation of comorbidity (such as presence of renal impairment or cardiac', 'insufficiency).', \"Data from standard-of-care procedures will be part of the patient's medical history and may be\", 'used for study purposes.', '11.3.', 'Efficacy Assessments', 'Efficacy evaluations will be performed as described below. Refer to Table 2, Table 4, Table 5,', 'Table 6, and Table 7 for the timing of all efficacy assessments.', '11.3.1.', 'Multiple Myeloma Disease Assessments', 'Patient response will be assessed by the procedures described in the following subsections and', 'graded according to the IMWG response criteria summarized in Table 17 (Kumar 2016). Per', 'IMWG, quantitative Ig levels by nephelometry may be used in place of SPEP for routine', 'M-protein measurement for patients with IgA or IgD myeloma. Also, per IMWG, response may', 'be confirmed if the patient fails to provide 24-hour urine sample collection after screening', 'activities occur. However, all MM disease assessments outlined below are required to be', 'performed at the study visits specified in Table 2, Table 4, Table 5, Table 6, and Table 7 and the', 'Investigator should make all attempts to collect all MM disease assessments at each time point as', 'outlined in this protocol.', 'Confidential', 'Page 73', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Patients randomized to the SVd and Vd Arms will undergo MM evaluations every 3 weeks from', 'baseline MM evaluations on C1D1 (regardless of drug holidays or drug interruptions) through', 'the first day of Week 37 (ie, 12 MM evaluations after C1D1) to identify patients who progress', 'quickly, then every 5 weeks for the remainder of the study regardless of cycle length (see Table 4', 'and Table 5). This will result in comparable PFS data from both arms. SVdX patients (Table 6)', 'and SdX patients (Table 7) will undergo MM evaluations every 5 weeks. If additional MM', 'disease assessments (ie, SPEP, urine protein electrophoresis [UPEP], serum FLC, quantitative Ig,', 'serum/urine protein immunofixation, and clinical plasmacytoma assessment) are performed at', 'unscheduled times, those results must be documented in the eCRF as unscheduled visits.', 'Samples on C1D1 must be collected either on Day -1 or predose on C1D1 for baseline values.', 'All MM disease assessments should be performed regardless of the diagnosis that is being', 'followed (ie, 24-hour urine collection for UPEP must be performed at each time point outlined in', 'the protocol even if the patient is being followed by SPEP).', 'Two consecutive assessments are needed to confirm response (Table 17). For patients who', 'achieve CR or sCR, confirmatory samples for SPEP with serum protein immunofixation,', 'quantitative Ig, and serum FLC must be collected in duplicate at the time of response and the', 'duplicate samples must be provided to the central laboratory. A confirmatory 24-hour urine', 'sample must also be collected, and an aliquot will be provided to the central laboratory for UPEP', 'with urine protein immunofixation. Refer to the Study Manual for details.', 'For the purposes of Risk-Based Monitoring activities, sites may be requested/required to provide', 'de-identified laboratory results (MM disease assessments) via the electronic data capture system.', 'Further instructions will be provided in the Study Manual.', 'Table 17:', 'International Myeloma Working Group Response Criteria, Myeloma', '(Kumar, 2016)', 'IMWG Response Criteria', 'Response Subcategory', 'Response Criteria', 'Complete response (CR)', 'Negative immunofixation of serum and urine, disappearance of any', 'soft tissue plasmacytomas, and <5% plasma cells in bone marrow', 'aspirates', 'Stringent complete response', 'CR as defined above plus normal FLC ratiod and absence of clonal', '(sCR)', 'cells in bone marrow biopsy by immunohistochemistry ratio', '<4:1 or >1:2 for K and a patients, respectively, after counting', '>100 plasma cellse', 'Very good partial response', 'Serum and urine M-protein detectable by immunofixation but not on', '(VGPR)', 'electrophoresis or 90% reduction in serum M-protein plus urine', 'Mprotein- level <100 mg per 24 hr', 'Partial response (PR)', '>50% reduction of serum M-protein plus reduction in 24-hr urinary', 'M-protein by >90% or to <200 mg/24 hr.', 'Confidential', 'Page 74', 'Version 4.0']\n\n###\n\n", "completion": "END"}